Prokidney (PROK) Income from Continuing Operations (2021 - 2026)
Prokidney's (PROK) quarterly Income from Continuing Operations came in at 42621000.0 in Q1 2026, down 12.3% year-on-year from 48599951.69 in Q1 2025, and down 390.69% on a QoQ basis from 8686000.0 in Q4 2025.
Prokidney (PROK) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Prokidney (PROK) has 6 years of Income from Continuing Operations data on file, last reported at 42621000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 12.3% year-over-year to 42621000.0 in Q1 2026; TTM through Mar 2026 was 124115000.0, a 25.21% increase from a year earlier, with the FY2025 full-year figure at 119446000.0, up 26.87% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 42621000.0, down from 8686000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for PROK reached as high as 8686000.0 in Q4 2025 and fell as low as 67486000.0 in Q1 2022.
- Historically, Income from Continuing Operations has averaged 35822588.24 across 5 years, with a median of 36909000.0 in 2023.
- Across the five-year window, Income from Continuing Operations tumbled 415505.63% in 2022 and soared 82.08% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 24573000.0 in 2022, then grew by 11.59% to 21724000.0 in 2023, then slumped by 123.18% to 48483000.0 in 2024, then surged by 82.08% to 8686000.0 in 2025, then slumped by 390.69% to 42621000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 42621000.0 in Q1 2026, 8686000.0 in Q4 2025, and 35843000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Prokidney | 96.00 Mn | 96.00 Mn | - | -42.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -42.62 Mn |
| Dec 31, 2025 | -8.69 Mn |
| Sep 30, 2025 | -35.84 Mn |
| Jun 30, 2025 | -36.97 Mn |
| Mar 31, 2025 | -37.95 Mn |
| Dec 31, 2024 | -48.48 Mn |
| Sep 30, 2024 | -41.05 Mn |
| Jun 30, 2024 | -38.47 Mn |
| Mar 31, 2024 | -35.33 Mn |
| Dec 31, 2023 | -21.72 Mn |
| Sep 30, 2023 | -41.99 Mn |
| Jun 30, 2023 | -34.82 Mn |
| Mar 31, 2023 | -36.91 Mn |
| Dec 31, 2022 | -24.57 Mn |
| Sep 30, 2022 | -33.95 Mn |
| Jun 30, 2022 | -22.13 Mn |
| Mar 31, 2022 | -67.49 Mn |
| Dec 31, 2021 | -13.82 Mn |
| Sep 30, 2021 | -17.02 Mn |
| Jun 30, 2021 | -5,325.00 |